JPM Global Healthcare Fund is an actively managed global healthcare fund with history going back to 2009. Its management company, J.P. Morgan Asset Management, is the asset management business of the listed financial group JPMorgan Chase & Co. The mandate covers pharmaceuticals, biotechnology, healthcare services, medical technology and life sciences.
Investment philosophy
The fund has a lasting tilt towards the largest companies by market capitalisation, with stable core positions in large, established companies.
The managers
Dominic Valder and Bartjan van Hulten share responsibility and are both healthcare specialists based in London. Valder has managed the fund since October 2022. He joined J.P. Morgan in 2020 from Fidelity International, where he was a senior analyst for the US healthcare sector, and has a background in pharmaceutical research and a degree in biochemistry from Oxford. He also manages the JDOC ETF. Van Hulten has been a healthcare analyst in J.P. Morgan's US equity research since 2018 and became co-manager in 2024. He previously founded the healthcare fund Medex Capital.
The portfolio
The portfolio has a lasting emphasis on pharmaceuticals and biotechnology, with North America as the largest region. Johnson & Johnson, Eli Lilly and AbbVie are examples of steady top holdings.
FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.
7 of 18 funds ranked on a calculated return
#9/ 18Year to date
+9.09% NOK
From NAV as of 16 Nov 2026
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#12/ 221 year
+11.90% NOK
From NAV as of 16 Nov 2026
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#12/ 223 years (ann.)
+7.23% NOK
From NAV as of 16 Nov 2026
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
#15/ 225 years (ann.)
+5.91% NOK
From NAV as of 16 Nov 2026
as of 13 Nov 2026 · Converted from USD to NOK
About the figures
9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.
Comparison basis
Year to date
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
1 year
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
3 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
5 years (ann.)
Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026
The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.